Page 64 - Read Online

Page 6 of 7 Weeda et al. Hepatoma Res 2021;7:43 https://dx.doi.org/10.20517/2394-5079.2021.10

Copyright
© The Author(s) 2021.

REFERENCES
1. Aronson DC, Meyers RL. Malignant tumors of the liver. Sem Ped Surg 2016;25:265-75.
2. Tanaka Y, Inoue T, Horie H. International pediatric liver cancer pathological classification: current trend. Int J Clin Oncol
2013;18:946-54. DOI PubMed
3. Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and
adolescents: A novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol 2002;39:510-8. DOI PubMed
4. Torbenson M. Review of the clinicopathological features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14:217-23. DOI PubMed
5. Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA: 2000-
2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. Unit
Europ Gastroenterol J 2013;1:351-7. DOI PubMed PMC
6. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer
2003;97:2006-12. DOI PubMed
7. Weeda VB, Murawski M, McCabe AJ, et al. Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than
conventional hepatocellular carcinoma in children: results and treatment recommendations for the Childhood Liver Tumour Strategy
Group (SIOPEL) experience. Eur J Cancer 2013;49:2698-704. DOI PubMed
8. Chang M, You S, Chen C, et al; Taiwan Hepatoma Study Group. Long-term effects of hepatitis B immunization of infants in
preventing liver cancer. Gastroenterol 2016;151:472-80. DOI PubMed
9. Meyers RL. Tumors of the liver in children. Surg Oncol 2007;16:195-203. DOI PubMed
10. Eichenmüller M, Trippel F, Kreuder M, Beck A, Schwarzmayr T, Haberle B, et al. The genomic landscape of hepatoblastoma and and
their progenies with HCC-like features. J Hepato ;61:1312-20. DOI PubMed
11. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010;2:105-18. PubMed PMC
12. Weeda VB, Aronson DC, Verheij J, Lamers WH. Is hepatocellular carcinoma the same disease in children and adults Comparison of
histology, molecular background and treatment in pediatric and adult patients. Pediatr Blood Cancer 2019;66:e27475. DOI PubMed
13. Bruix J, Qin S, Merle P, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on
sorafenib treatment (RESORCE): a randomized, double-blind, placebo/controlled, phase 3 trial. Lancet 2017;389:56-66. DOI
PubMed
14. Schmid I, Haberle B, Albert MH, et al. Sorafenib and cisplatin-doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr
Blood Cancer 2012;58:539-44. DOI PubMed
15. Aronson DC, Weeda VB, Maibach R, et al; Childhood Liver Tumour Strategy Group (SIOPEL). Microscopically positive resection
margin after hepatoblastoma resection: what is the impact on prognosis? Eur J Cancer 2019;106:126-32. DOI PubMed
16. Ziogas IA. Benedetti DJ, Matsuoka LK, et al. Surgical management of pediatric hepatocellular carcinoma: An analysis of the National
Cancer Database. J Pediatr Surg 2020;S0022-3468(20)30433-4. DOI PubMed
17. Czauderna P, Mackinlay G, Perilongo G, et al; Liver Tumors Study Group of the International Society of Pediatric Oncology.
Hepatocellular carcinoma in children: Results of the first prospective study of the International Society of Pediatric Oncology group. J
Clin Oncol 2002;20:2798-804. DOI PubMed
18. Murawski M, Weeda VB, Maibach RM, Morland B, Roebuck D, Zimmerman A, et al. Hepatocellular Carcinoma in Children: Does
modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? J Clin Oncol
2016;34:1050-6. DOI PubMed
19. Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017;4:15-21.
DOI PubMed PMC
20. Katzenstein HM, Krailo MD, Malogolowkin MH, et al. Hepatocellular Carcinoma in Children and Adolescents: Results from the
Pediatric Oncology Group and the Children’s Cancer Group Intergroup Study. J Clin Oncol 2002;20:2789-97. DOI PubMed
21. Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular
carcinoma: Results from a phase I extension trial. Eur J Cancer 2009;45:579-87. DOI PubMed
22. Liu Y, Yue H, Xu S, et al. First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance
therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. Int J Clin Oncol 2015;20:952-9. DOI PubMed
st
23. Assenat E, Pageaux GP, Thézenas S, et al. Sorafenib alone vs. sorafenib plus GEMOX as 1 -line treatment for advanced HCC: the
phase II randomized PRODIGE 10 trial. Br J Cancer 2019;120:896-902. DOI PubMed PMC
24. Gras P, Truant S, Boige V, et al. Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar
hepatocellular carcinoma. Case Rep Oncol 2012;5:69-72. DOI PubMed PMC
25. Haines K, Sarabia SF, Alvarez KR, et al. Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and
diverse signaling pathway activation. Pediatr Blood Cancer 2019;66:e27745. DOI PubMed
26. Cho SJ. Pediatric liver tumors: Updates in classification. Surg Pathol Clin 2020;13:601-23. DOI PubMed
27. Ranganathan S, Lopez-Terrada D, Alaggio R. Hepatoblastoma and pediatric hepatocellular carcinoma: An update. Pediatr Dev Pathol
2020;23:79-95. DOI PubMed
28. Aguado A, Ristagno R, Towbin AJ, et al. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy
in children. Pediatr Blood Cancer 2019;66:e27510. DOI PubMed